

Oncology Today with Dr Neil Love: Key Presentations on Lymphoma from Recent Major Conferences

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- In the Phase III SWOG-S1826 study comparing nivolumab/AVD to brentuximab vedotin/AVD for newly diagnosed Hodgkin lymphoma, what was the reported efficacy outcome?**
 - The 1-year progression-free survival (PFS) rate was higher with brentuximab vedotin/AVD
 - The 1-year PFS rate was higher with nivolumab/AVD**
 - The 1-year PFS rate was equivalent between the 2 treatment arms
- Which regimen was FDA approved in March 2024 for relapsed or refractory follicular lymphoma after 2 or more lines of systemic therapy?**
 - Acalabrutinib in combination with rituximab
 - Zanubrutinib in combination with obinutuzumab**
 - Ibrutinib in combination with venetoclax
 - Pirtobrutinib in combination with rituximab
- Pirtobrutinib is a Bruton tyrosine kinase inhibitor that is currently approved for which B-cell lymphoma?**
 - Follicular lymphoma
 - Mantle cell lymphoma**
 - Diffuse large B-cell lymphoma (DLBCL)
 - All of the above
 - None of the above – pirtobrutinib is not currently approved for any B-cell lymphoma
- In a Phase II study of fixed-duration glofitamab monotherapy for relapsed/refractory DLBCL, what was the reported complete response rate?**
 - 0%
 - 15%
 - 40%**
 - 90%
- Which of the following CAR (chimeric antigen receptor) T-cell therapies has demonstrated meaningful clinical activity in relapsed/refractory follicular lymphoma?**
 - Tisagenlecleucel
 - Axicabtagene ciloleucel
 - Lisocabtagene maraleucel
 - All of the above**
 - None of the above